GlassScriptPhysician profile
Dinesh K Bhatt
NPI 1053408815
$682.44
in general payments reported to CMS, 2019-2025
10 companies · $51.39 in 2025
The $51.39 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $85.75 · 2021: $202 · 2023: $106 · 2024: $14.33 · 2025: $51.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $213.02 | 2021-2023 | Verquvo |
| Vifor Pharma, INC. | $157.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.65 | 2019-2020 | |
| Pfizer INC. | $65.75 | 2020 | |
| Biotronik INC. | $55.50 | 2023-2025 | Biomonitor |
| Boston Scientific Corporation | $54.77 | 2021 | |
| Medtronic, INC. | $18.60 | 2025 | Linq II |
| Lexicon Pharmaceuticals, INC. | $17.81 | 2023 | Inpefa |
| Amarin Pharma, INC. | $17.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.33 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.